Accessibility Menu
Immuron logo

Immuron(ASX) IMC

Market CapA$12.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)-99%
5 Year-76%
1 Year-43%
1 Month-9%
A$0.04
+5.41%
+0.00Today
Immuron last closing stock price
MetricPriceDate
Last closeAUD 0.042026-08-13
Immuron stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+21.87%AUD 0.032026-08-06
1 month-9.3%AUD 0.042026-07-13
3 month+18.18%AUD 0.032026-05-15
Year to date+8.33%AUD 0.042025-12-31
1 year-42.65%AUD 0.072025-08-11
3 year-50%AUD 0.082023-08-14
5 year-75.63%AUD 0.162021-05-26
Since inception-99.37%AUD 6.191999-04-30

Immuron Financials at a Glance

Market Cap

A$12.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$14.02M

Net Income (TTM)

-A$12.00M

EPS (TTM)

-A$0.02

P/E Ratio

-2.09

Dividend

A$0.00

Beta (Volatility)

-0.03 (Low)

Price

A$0.04

Volume

0

Open

A$0.04

Previous Close

A$0.04

Daily Range

A$0.04 - A$0.04

52-Week Range

A$0.03 - A$0.10

Estimated Earnings Date

Aug 28, 2026

IMC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immuron

Immuron Limited is an Australian biopharmaceutical company focused on the development and commercialization of polyclonal antibodies. Established in 1994 and headquartered in Carlton, the company operates in the biotechnology sector, offering innovative solutions for gastrointestinal health and immune support.

Products and Services
  • Travelan: An over-the-counter remedy for travelers' diarrhea and digestive health
  • Protectyn: An immune supplement for digestive function and liver support
  • Pipeline candidates: Including IMM-124E and IMM-529 for gastrointestinal infections
Growth Outlook
  • Travelan is in Phase III trials in the U.S. for travelers' diarrhea prevention
  • IMM-529 is advancing in Phase I/IIa trials for recurrent Clostridium difficile infections
  • Strategic alliances with military research institutes enhance product development
Financial Highlights
  • Recent quarterly revenue of 4.18 million AUD, showing growth from previous quarters
  • Cash and cash equivalents of 9.99 million AUD, providing a solid financial foundation
  • Current ratio of 8.04 indicates strong liquidity and financial health
Immuron Limited is positioned to capitalize on the growing demand for innovative healthcare solutions. The company's focus on research and development, combined with its strategic partnerships, enhances its potential for future growth. Recent financial performance indicates a positive trajectory, with increasing revenues and a robust cash position. The ongoing clinical trials for key products further underscore the company's commitment to advancing its portfolio and addressing unmet medical needs in gastrointestinal health.
AI Generated • Jul 24, 2026

Industry

Biotechnology

CEO

Steven Lydeamore, MBA

Headquarters

Carlton, VIC 3053, AU

IMC Financials

Key Financial Metrics (TTM)

Gross Margin

63.69%

Operating Margin

-68.38%

Net Income Margin

-62.14%

Return on Equity

-43.95%

Return on Capital

-65.29%

Return on Assets

-30.69%

Earnings Yield

-47.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$12.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

322.85M

Volume

0

Avg. Volume

276.71K

Financials (TTM)

Gross Profit

A$9.18M

Operating Income

-A$9.70M

EBITDA

-A$10.97M

Operating Cash Flow

-A$12.49M

Capital Expenditure

-A$4.95K

Free Cash Flow

-A$12.49M

Cash & ST Invst.

A$10.00M

Total Debt

A$0.00

Immuron Performance Analysis

Immuron annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 765,193N/A
20232023-06-30AUD 1,804,705135.8%
20242024-06-30AUD 4,902,865171.7%
20252025-06-30AUD 7,287,00248.6%
Immuron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-308.1%
Q22024-12-3156.8%
Q42025-06-30-17.6%
Q22025-12-3127.1%
Immuron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.0232.8%
20242024-06-30AUD -0.0383.1%
20252025-06-30AUD -0.02-25.7%
Immuron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-134.1%
Q22024-12-3148.8%
Q42025-06-30-7.3%
Q22025-12-3140.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$4.18M

+77.6%

Gross Profit

A$2.65M

+67.9%

Gross Margin

63.42%

N/A

Market Cap

A$12.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.80M

N/A

Employees

7

N/A

Net Income

-A$1.92M

+7.4%

EBITDA

-A$2.31M

-24.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$10.00M

-39.1%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$2.52M

+351.3%

Inventory

A$2.24M

+38.4%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$0.00

-100.0%

Return on Assets

-30.69%

N/A

Return on Invested Capital

-38.50%

N/A

Free Cash Flow

-A$2.48M

-23.8%

Operating Cash Flow

-A$2.48M

-23.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NTI.AXNeurotech International Limited
A$0.01+0.00%
PAB.AXPatrys Limited
A$0.03-3.13%
AT1.AXAtomo Diagnostics Limited
A$0.02-5.56%
TRP.AXTissue Repair Ltd
A$0.09-1.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About IMC

What is the current price of Immuron?

Immuron is trading at A$0.04 per share.

What is the 52-week range for Immuron?

Over the past 52 weeks, Immuron has traded between A$0.03 and A$0.10.

How much debt does Immuron have?

As of the most recent reporting period, Immuron reported total debt of A$0.00.

How much cash does Immuron have on hand?

Immuron reported A$2.83M in cash and cash equivalents in its most recent financial results.

What is Immuron’s dividend yield?

Immuron does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.